KdT Ventures positions itself as the standard for early stage frontier science investing. The firm's core observation is that while software has transformed the digital world, the physical layer of medicine, chemicals and materials has barely changed, and that advances in computation and biology now put that physical layer in play. KdT writes first institutional checks, typically 500 thousand to 5 million dollars at pre-seed and seed, into founders engineering matter at the level of molecules, atoms and living systems. The portfolio spans therapeutics, diagnostics, synthetic biology, industrial biotechnology, new materials, digital health and scientific tools, with companies such as Terray Therapeutics, Dyno Therapeutics, Solugen, PathAI and Azitra among those backed since the firm's founding by physician Cain McClary in 2017. The investment team is unusually technical, with most members holding advanced scientific, medical or legal degrees, and the firm leans on that depth to underwrite scientific risk at inception and to help founders design companies, recruit teams and structure early partnerships. Now investing from an oversubscribed fourth fund of more than 100 million dollars closed in October 2024, KdT manages over 250 million dollars and has backed more than 65 companies across the physical layer supply chain.
Skin microbiome company Azitra, a KdT Fund I portfolio company, completed its initial public offering on NYSE American in June 2023 and trades under the ticker AZTR.